Effects of TRPM8 on the proliferation and angiogenesis of prostate cancer PC-3 cells in vivo

Oncology Letters

Volumn 2, Issue 6, 2011, Pages 1213-1217

  Zhu, Guangbin ^a   Wang, Xinghuan ^a   Yang, Zhonghua ^a   Cao, Hong ^a   Meng, Zhe ^a   Wang, Yongzhi ^a   Chen, Dong ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Proliferation; Prostate cancer; TRPM8

Indexed keywords

CD34 ANTIGEN; CYCLINE; FOCAL ADHESION KINASE; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 80052768927     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.410     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Martel CL, Gumerlock PH, Meyers FJ and Lara PN: Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 29: 171-187, 2003.
3. Berridge MJ, Lipp P and Bootman MD: The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 1: 11-21, 2000.
4. Tsavaler L, Shapero MH, Morkowski S and Laus R: Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 61: 3760-3769, 2001.
5. Henshall SM, Afar DE, Hiller J, et al: Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63: 4196-4203, 2003.
6. 2+ channel required for the survival of prostate cancer cells. Cancer Res 64: 8365-8373, 2004.
7. Yang ZH, Wang XH, Wang HP and Hu LQ: Effects of TRPM8 on the proliferation and motility of prostate cancer PC-3 cells. Asian J Androl 11: 157-165, 2009.
8. Folkman J: Tumor angiogenesis: therapeutic implications. NEngl J Med 285: 1182-1186, 1971.
9. Brawer MK, Deering RE, Brown M, Preston SD and Bigler SA: Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 73: 678-687, 1994.
10. Ferrer FA, Miller LJ, Andrawis RI, et al: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157: 2329-2333, 1997.
11. Jackson MW, Bentel JM and Tilley WD: Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 157: 2323-2328, 1997.
12. Borre M, Nerstrom B and Overgaard J: Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 6: 1882-1890, 2000.
13. Warri AM, Huovinen RL, Laine AM, Martikainen PM and Harkonen PL: Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 85: 1412-1418, 1993.
14. Parsons JT, Slack-Davis J, Tilghman R and Roberts WG: Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res 14: 627-632, 2008.
15. Chang YM, Kung HJ and Evans CP: Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 9: 90-100, 2007.
16. Voets T, Owsianik G and Nilius B: Trpm8. Handb Exp Pharmacol 329-344, 2007.
17. Gkika D, Flourakis M, Lemonnier L and Prevarskaya N: PSA reduces prostate cancer cell motility by stimulating TRPM8 activity and plasma membrane expression. Oncogene 29: 4611-4616, 2010.
18. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
19. Ferrer FA, Miller LJ, Lindquist R, et al: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54: 567-572, 1999.
20. Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A and Biagini G: Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 45: 72-79, 2000.
21. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML and Merino MJ: Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147: 33-41, 1995.
22. Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993.
23. Kosaka T, Miyajima A, Takayama E, et al: Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 67: 41-49, 2007.
24. Tanaka S, Haruma K, Tatsuta S, et al: Proliferating cell nuclear antigen expression correlates with the metastatic potential of submucosal invasive colorectal carcinoma. Oncology 52: 134-139, 1995.
25. Lacoste J, Aprikian AG and Chevalier S: Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility. Mol Cell Endocrinol 235: 51-61, 2005.
26. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE and Parsons JT: Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 20: 1152-1163, 2001.